Futura Medical PLC
FUM
Company Profile
Business description
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction (commercially available in multiple markets), Eroxon Intense (a new line extension in development) and WSD4000 which is in-development female sexual health portfolio. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union followed by USA and rest of the world.
Contact
40 Occam Road
Surrey Technology Centre
GuildfordSurreyGU2 7YG
GBRT: +44 1483685670
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.90 | 24.70 | -0.27% |
| CAC 40 | 8,366.85 | 2.20 | 0.03% |
| DAX 40 | 25,147.03 | 32.78 | 0.13% |
| Dow JONES (US) | 52,508.27 | 9.63 | 0.02% |
| FTSE 100 | 10,529.39 | 31.10 | 0.30% |
| HKSE | 24,695.62 | 354.89 | 1.46% |
| NASDAQ | 26,107.01 | 233.83 | 0.90% |
| Nikkei 225 | 68,554.30 | 810.80 | 1.20% |
| NZX 50 Index | 13,595.52 | 55.70 | -0.41% |
| S&P 500 | 7,543.59 | 28.25 | 0.38% |
| S&P/ASX 200 | 8,830.30 | 26.70 | -0.30% |
| SSE Composite Index | 3,963.90 | 3.22 | -0.08% |